Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics

Wednesday, April 30, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

PARIS, April 30 ExonHit Therapeutics S.A.(Alternext: ALEHT), a drug and diagnostic discovery company, announceschanges in its Supervisory Board.

Following the annual shareholders' meeting of the Company, that was heldon April 25th, 2008, Mr. Edmund Olivier de Vezin's appointment as member ofthe Supervisory Board, and as vice-chairman of the Board, expired as he hasreached the age limit defined in the Company by-laws. The Supervisory Boardthen appointed Mr. Patrick Langlois, who had just been re-elected during theshareholders'meeting, as vice-chairman of the Board.

ExonHit Therapeutics'shareholders have also elected Mr. FredericDesdouits, Ph.D. as member of the Supervisory Board.

Mr. Desdouits has been a partner with Bionest Partners, a consultancyfirm focused on Life Sciences since 2005. Before joining Bionest, Fredericwas head of Pharma Equity Research and a partner at Exane BNP Paribas. Healso was head of a research team at GlaxoWellcome, and a ScientificConsultant for Hoechst and Guest Investigator at the Rockefeller University,New York, where he worked on Alzheimer's Disease. Frederic holds a Ph.D. fromthe College de France in collaboration with Rhone-Poulenc. He holds an MSc inpharmacology and is a graduate of Ecole Polytechnique. He is also a member ofthe ACIIA.

"I am delighted to join the Supervisory Board of ExonHit and look forwardto contributing to the analysis of strategic opportunities for the growth ofExonHit, based on my experience as a scientist, finance person andconsultant" said Mr. Desdouits.

The Supervisory Board is chaired by Mr. Laurent Condomine, and Mr.Patrick Langlois is vice-chairman. The other Board members are Ms. DeborahSmeltzer, Mr. Christophe Jean, Mr. Michel Picot and Mr. Frederic Desdouits.

"We are very pleased to have Frederic Desdouits sitting on theSupervisory Board of ExonHit Therapeutics. His professional background, hisknowledge of shareholder expectations and of the competitive environment ofthe Life Science industry will be a strategic asset to ExonHit" said PhilippeRousseau, Chairman of the Management Board of ExonHit. "Also, we are verygrateful to Mr. Edmund Olivier de Vezin for his valuable advice, hisunwavering support and his active participation in ExonHit's developmentduring the ten years he has spent with the Company's Board. Mr. Olivier deVezin, who represents the Oxford BioSceince Partners funds, invested inExonHit since its inception and remains ExonHit's first shareholder. We arevery happy that Mr Olivier de Vezin continues to support with confidence theCompany development through the funds he manages."

About ExonHit Therapeutics

ExonHit Therapeutics is the world's leader in the analysis of alternativeRNA splicing, a process which when deregulated plays a key role in the onsetof various diseases.

ExonHit has a multi-component commercial strategy to capture the maximumvalue from its leadership in alternative splicing. The Company is alreadygenerating revenues from a new generation of microarrays, SpliceArrayTMfamily of products that enable life science researchers to detect crucialdisease-associated information. These products are marketed worldwide inconjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHithas a major collaboration with bioMerieux to develop completely novelpredictive blood-based cancer diagnostics, which could play a key role inimproving the treatment of breast cancer and other major cancers and developsits own projects for the detection of other chronic diseases such asAlzheimer' disease or atherosclerosis.

In parallel, ExonHit is developing its own therapeutic pipeline in thefield of neurodegenerative diseases and cancer. The Company has advanced drugcandidates into clinical trials and is evaluating several promisingpre-clinical compounds. ExonHit also has a

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store